Video

Dr. Rugo on the Optimal Setting for Biosimilar Evaluation

Author(s):

Hope Rugo, MD

In Partnership With:

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the optimal setting for biosimilar evaluation.

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the optimal setting for biosimilar evaluation.

In an analysis of trastuzumab (Herceptin) biosimilars in breast cancer, investigators compared studies in the neoadjuvant and metastatic settings to determine which setting was more favorable for testing biosimilars. Half of the studies evaluated were in the neoadjuvant setting, while the other half were in the metastatic setting. By closely considering the way in which the studies wereconducted as well as the results they yielded, Rugo felt that they would be able to answer this question.

Investigators found that the neoadjuvant and metastatic settings are equally good settings to evaluated biosimilarity. Data collected in both settings could be used to extrapolate the use of trastuzumab biosimilars in other settings, with other combinations, and in other diseases in which trastuzumab is used, she adds. Rugo notes that patients in each group were relatively homogenous in terms of amount of visceral disease.

This information is beneficial, Rugo adds, as it may lead to trastuzumab biosimilar availability in countries that cannot afford the originator biologic.

Related Videos
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD
Janaki Neela Sharma, MD
Karine Tawagi, MD,
Vered Stearns, MD
Related Content
Neil P. Shah, MD, PhD
December 1st 2024

The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Alan P. Venook, MD
November 25th 2024

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology

Hope Rugo, MD, FASCO, of UCSF Helen Diller Family Comprehensive Cancer Center
October 31st 2024

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer